Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis
Abstract Background Imatinib is the standard first‐line treatment for advanced gastrointestinal stromal tumors (GISTs); however, most patients eventually develop imatinib resistance, leading to considerable clinical challenges. Few direct comparisons have been made between different post‐first‐line...
Main Authors: | Kehan Hu, Hu Zhang, Mingrong Shu, Xingyue Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-06-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.5912 |
Similar Items
-
Safety of Regular-Dose Imatinib Therapy in Patients with Gastrointestinal Stromal Tumors Undergoing Dialysis
by: Ryota Niikura, et al.
Published: (2016-05-01) -
Imatinib Mesylate Therapy in Advanced Gastrointestinal Stromal Tumors: Experience from a Single Institute
by: Hui-Hua Hsiao, et al.
Published: (2006-12-01) -
Imatinib-Resistant Gastrointestinal Stromal Tumor Presenting as a Large Abdominal Mass
by: Asim Haider, et al.
Published: (2021-08-01) -
Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
by: Xiangchen Hu, et al.
Published: (2022-09-01) -
Surgical intervention of a giant gastric gastrointestinal stromal tumor following neoadjuvant therapy with imatinib
by: Chien-Yang Wang, et al.
Published: (2018-01-01)